AVITA's Q4 sales missed guidance due to hospitals deferring year end purchases. However, January's rebound suggests a strong ...

AVITA Medical (NASDAQ:RCEL – Get Free Report) will likely be posting its quarterly earnings results after the market closes ...

We came across a bullish thesis on AVITA Medical, Inc. (RCEL) on Substack by Steve Wagner. In this article, we will summarize ...

D. Boral Capital reaffirmed their buy rating on shares of AVITA Medical (NASDAQ:RCEL – Free Report) in a report issued on Friday,Benzinga reports. The firm currently has a $25.00 price objective on ...

D. Boral Capital lowered the firm’s price target on Avita Medical (RCEL) to $22 from $25 and keeps a Buy rating on the shares. The CFO of Avita ...

Last year, technology group Altilium launched an online platform for end-of-life electric vehicle (EV) batteries. The recell.store platform offers an interface for businesses in the UK looking to sell ...

We expect Avita to be cash flow positive in 2026. We expect Avita’s RECELL to pose a significant challenge to the standard of care for larger burns, currently a skin graft sourced from elsewhere on ...

AVITA's growth strategy revolves around its robust product pipeline and efforts to expand into new markets. The company is focusing on several key products and initiatives: 1. RECELL GO: This product ...

Commercialisation of the Company's regenerative product.

Asus VivoBook 15 X412DA-EK504T Ultrabook (AMD Quad Core Ryzen 5/8 GB/512 GB SSD/Windows 10) Rs. 42,990 ...